rationale chronic obstructive lung disease copd common disabling lung disease therapeutic options objectives reasoned gene expression profiling copd lungs reveal previously unidentified disease pathways methods human lung samples obtained tissue resected nonsmokers NUMBER gold global initiative chronic obstructive lung disease stage NUMBER NUMBER gold stage NUMBER NUMBER gold stage NUMBER NUMBER gold stage NUMBER patients mrna specimens profiled using agilents functional id v20 array agilent santa clara ca containing NUMBER sequences measurements main results gene expression pattern influenced percentage sample parenchyma gene expression related forced expiratory flow NUMBER NUMBER forced expiratory volume predicted revealing signature gene set NUMBER transcripts genes involved extracellular matrix apoptosis genes genes participate antiinflammatory responses immunohistochemistry confirmed expression urokinase plasminogen activator plau urokinase plasminogen activator receptor plaur thrombospondin thbs1 alveolar macrophages airway epithelial cells genes pathway shown involved activation transforming growth factor matrix metalloproteinases subject inhibition serpine2 interestingly serpine2 identified candidate genes copd genetic linkage association studies conclusions results provide evidence genes involved tissue remodeling repair differentially regulated lungs obstructed smokers suggest potential therapeutic targets data deposited geo fef25 NUMBER regulated regulated tgf beta1 tgf beta1 synthesis degradation http wwwncbinlmnihgov geo query acccgiaccgse8500